Smartphone-Based DNA Diagnostics Detects Malaria
|
By LabMedica International staff writers Posted on 16 Aug 2021 |

Image: Smartphone-based DNA diagnostics for malaria detection using deep learning for local decision support and blockchain technology for security (Photo courtesy of University of Glasgow)
There remains a substantial burden from infectious disease in low-resource rural communities, not least as a consequence of malaria. In infectious disease diagnosis, results need to be communicated rapidly to healthcare professionals once testing has been completed so that care pathways can be implemented.
Diagnostic testing continues to underpin control and prevention strategies, primarily through the use of rapid, point-of-care, lateral flow immunoassays, which are affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable devices. This represents a particular challenge when testing in remote, low-resource rural communities, in which such diseases often create the largest burden.
Bioengineers at the University of Glasgow (Glasgow, UK) and their colleagues developed a smartphone-based end-to-end platform for multiplexed DNA diagnosis of malaria. The diagnostic platform comprises both hardware and software. The hardware includes a three-dimensional (3D) printed mobile heater for loop-mediated isothermal amplification (LAMP)-based diagnostics as well as a mobile phone and a low-cost disposable sensor cartridge, while the software includes an Arduino program, an Android app and a Hyperledger blockchain network.
The team field tested the platform on blood samples collected from 40 school children from Uganda, and compared their results with the gold-standard PCR assay. The team also used malaria rapid immunodiagnostic tests (RDT) for comparison.
The scientists reported that of the 28 tests that were correctly assigned and valid, 16 were true positives (positive for the manually recorded test, the blockchain records and real-time PCR), six were true negatives, three were false negatives and three were false positives (with respect to the gold standard). The blockchain implementation ensured the security of transactions, opening up the possibility for integration into surveillance databases, while maintaining the required safety around data privacy.
The authors concluded that the smartphone-based end-to-end platform they had developed for multiplexed DNA-based lateral flow diagnostic assays that can be used in remote, low-resource settings. Their decision support tool provides automated detection of the results and their analysis, supporting human expertise, and transactions involved in data handling are secured, trusted and endorsed using blockchain technology. The study was published on August 2, 2021 in the journal Nature Electronics.
Related Links:
University of Glasgow
Diagnostic testing continues to underpin control and prevention strategies, primarily through the use of rapid, point-of-care, lateral flow immunoassays, which are affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable devices. This represents a particular challenge when testing in remote, low-resource rural communities, in which such diseases often create the largest burden.
Bioengineers at the University of Glasgow (Glasgow, UK) and their colleagues developed a smartphone-based end-to-end platform for multiplexed DNA diagnosis of malaria. The diagnostic platform comprises both hardware and software. The hardware includes a three-dimensional (3D) printed mobile heater for loop-mediated isothermal amplification (LAMP)-based diagnostics as well as a mobile phone and a low-cost disposable sensor cartridge, while the software includes an Arduino program, an Android app and a Hyperledger blockchain network.
The team field tested the platform on blood samples collected from 40 school children from Uganda, and compared their results with the gold-standard PCR assay. The team also used malaria rapid immunodiagnostic tests (RDT) for comparison.
The scientists reported that of the 28 tests that were correctly assigned and valid, 16 were true positives (positive for the manually recorded test, the blockchain records and real-time PCR), six were true negatives, three were false negatives and three were false positives (with respect to the gold standard). The blockchain implementation ensured the security of transactions, opening up the possibility for integration into surveillance databases, while maintaining the required safety around data privacy.
The authors concluded that the smartphone-based end-to-end platform they had developed for multiplexed DNA-based lateral flow diagnostic assays that can be used in remote, low-resource settings. Their decision support tool provides automated detection of the results and their analysis, supporting human expertise, and transactions involved in data handling are secured, trusted and endorsed using blockchain technology. The study was published on August 2, 2021 in the journal Nature Electronics.
Related Links:
University of Glasgow
Latest Microbiology News
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
Channels
Clinical Chemistry
view channel
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more
Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







